Senior Fellow, National Center for Policy Analysis
Senior Fellow at the National Center for Policy Analysis (NCPA) and author of Free To Choose Medicine: Better Drugs Sooner at Lower Cost
Adjunct Fellow, Competitive Enterprise Institute
Gregory Conko is an Adjunct Fellow at the Competitive Enterprise Institute and Vice President of Programs at DonorsTrust. His research at CEI focuses on health care, food and drug regulation, agriculture and agricultural trade, and nutrition and public health. He also has broad expertise in science and environmental policy and in administrative and regulatory law.
Since 2021, Conko has managed the grants and grantee programs at the donor-advised fund sponsor DonorsTrust, but he continues to research and write on policy matters for the Competitive Enterprise Institute. Before joining DonorsTrust, Conko was Deputy Director of the George Mason University Law & Economics Center, a Senior Fellow and later Executive Director of CEI.
Conko is the author or co-author of numerous books, studies, and articles, and Barron’s called his book, The Frankenfood Myth: How Protest and Politics Threaten the Biotech Revolution, co-authored with Henry I. Miller, one of the 25 best books of 2004. His other writings have appeared in such journals as Nature Biotechnology, Transgenic Research, Health Matrix: Journal of Law & Medicine, and the Cumberland Law Review, and in such newspapers as the Financial Times, The Wall Street Journal, Los Angeles Times, and USA Today.
Conko is a member of the Federalist Society’s Regulatory Transparency Project Working Group on FDA & Health, a member of the American Council on Science and Health’s Board of Scientific and Policy Advisors. He received a JD degree magna cum laude from the George Mason University School of Law and a BA in political science and history from American University. He lives in Virginia with his wife and son.
Partner, Hollingsworth LLP, Washington, DC.
Mr. Lasker litigates a wide variety of complex civil matters, with a current focus on toxic torts, environmental litigation, Alien Tort Statute litigation, and pharmaceutical products liability. Mr. Lasker has also represented clients in a variety of civil and criminal government investigation-related matters involving bank regulatory compliance, False Claims Act claims, and alleged price fixing, and he served as lead counsel in successfully defending a foreign client against a Foreign Corrupt Practices claim in a jury trial that was featured in the Legal Times. He represents clients in jury and bench trials, before arbitral panels and administrative courts, and both at trial and on appeal.
Mr. Lasker has significant experience defending against all matter of legal claims involving FDA- and EPA-regulated products and alleged toxins and environmental contaminants. He has represented clients in pharmaceutical products liability claims involving antipsychotic medications, obstetrical drugs, antifungals, antiepileptics, and cough/cold medicines, and in toxics/environmental matters involving herbicides, asbestos, lead paint, nonionizing radiation, and chemical solvents. He has represented clients in matters arising both in the United States and abroad, and in matters arising under both domestic and international law. Mr. Lasker's practice also includes matters involving sensitive national security issues, and he has represented his clients’ interests in meetings with both U.S. and foreign government officials. He has extensive expertise in developing and implementing sophisticated medical causation and science-based defenses, and he has successfully litigated issues involving Daubert, the federal preemption defense, and natural resource damages claims. He also assists clients in due diligence investigations as relates to environmental and toxics liabilities and through amicus briefing on key legal issues.
Mr. Lasker played a prominent role in helping to establish asbestos defendants’ rights to insurance non-products coverage through a successful amicus effort that secured one of the seminal judicial opinions recognizing the existence of such coverage, litigation efforts resulting in securing several hundreds of millions of dollars in asbestos non-products insurance recoveries, and oral presentations and publications on issues involving non-products coverage. He has also defended personal injury claims in asbestos litigation, advancing medical causation defenses as the asbestos litigation has extended to tertiary and even more remotely-situated corporate defendants.
Mr. Lasker is frequently requested to speak and publish on issues of interest to his clients, and he has been interviewed on such topics in numerous fora, including the AMA's American Medical News, Bloomberg News, the National Law Journal, and thePhiladelphia Inquirer. Mr. Lasker serves on the Board of Editors of LJN's Product Liability Law & Strategy newsletter and he is the Chair of the Toxics & Hazardous Substances Committee of the International Association of Defense Counsel (IADC), an invitation-only professional association for corporate and insurance defense attorneys around the world. He also serves as a member of the Defense Research Institute (DRI).
Partner and Co-Chair, Public Policy Group, Shook Hardy & Bacon LLP
Mark Behrens co-chairs Shook's Washington, DC-based Public Policy Practice Group and is a leading national expert on civil justice issues with over thirty years of experience. A substantial part of his practice is working to improve the civil litigation environment through state and federal legislation; in the courts through amicus curiae briefs; through legal scholarship and judicial education; and in the court of public opinion.
Mark is actively involved in civil justice reform efforts at the federal and state levels. He has testified before the U.S. Congress and most state legislatures on behalf of business and civil justice organizations. Mark also has an active amicus brief practice specializing in tort liability and civil justice issues. He has authored or co-authored over 150 amicus briefs in cases before the United States Supreme Court and federal and state appellate courts on behalf of business, civil justice, and defense lawyer organizations. In addition, Mark routinely files comments on behalf of business, civil justice, and defense lawyer organizations regarding potential changes to federal and state court rules. He chairs the International Association of Defense Counsel’s (IADC) Civil Justice Response Committee and serves on the Board of Directors of Lawyers for Civil Justice (LCJ).
Mark is a member of the American Law Institute (ALI). He received his J.D. in 1990 from Vanderbilt University Law School, where he was a member of the Vanderbilt Law Review. He received his B.A. in economics from the University of Wisconsin in 1987.
Director of Litigation and Senior Attorney, Hamilton Lincoln Law Institute
Theodore H. Frank is director at the Hamilton Lincoln Law Institute and the Center for Class Action Fairness. Frank founded and ran CCAF as a non-profit, public interest law firm in 2009.
Frank has won several landmark appeals and tens of millions of dollars for consumers and other plaintiffs through his class action work. Adam Liptak of The New York Times calls Frank “the leading critic of abusive class action settlements” and the American Lawyer Litigation Daily referred to him as “the indefatigable scourge of underwhelming class action settlements.”
Previously, Frank clerked for the Honorable Frank H. Easterbrook on the Seventh Circuit Court of Appeals, and was a litigator at firms in Washington and Los Angeles and a resident fellow at the American Enterprise Institute. Frank is a frequent public speaker and has testified before Congress multiple times on legal issues. He has been profiled by The Wall Street Journal, Forbes, GQ, and the ABA Journal, among other publications.
In 2008, Frank was elected to membership in the American Law Institute. He also serves on the Executive Committee of the Federalist Society Litigation Practice Group. Frank graduated from The University of Chicago Law School in 1994 with high honors and as a member of the Order of the Coif and the Law Review. He is a member of the District of Columbia Bar and the state bars of California and Illinois.
Free To Choose Medicine
Bartley J. Madden, Gregory Conko
Note from the Editor: This article is about the Free To Choose Medicine concept....
Holding Pharma Plaintiffs to Their Pleading Burden: Implications of Twombly and Iqbal
Eric Lasker, Michael Junk
State and federal courts nationwide are home to a staggering number of pharmaceutical product liability...
Vioxx Settlement: State AGs’ New Rights to Enforce Food & Drug Law
Jennifer Wolsing
In May 2008, Merck entered into a $58 million, 29-state Vioxx settlement. Payouts begin in...
Mark A. Behrens Reviews "Mass Torts in a World of Settlement" by Richard A. Nagareda
Mark A. Behrens
Vanderbilt Law Professor Richard Nagareda’s recent book, Mass Torts in a World of Settlement, explores...
The Vioxx Settlement
Washington, District of ColumbiaThe Vioxx Litigation
Theodore "Ted" Frank
On September 30, 2004 , Merck withdrew its painkiller Vioxx from the market because of...